참고문헌
- Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13 Suppl 2:1-9.
- Corso A, Klersy C, Lazzarino M, Bernasconi C. Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol 1998;76:67-72. https://doi.org/10.1007/s002770050365
- Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30:493-501. https://doi.org/10.3109/10428199809057562
- Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 2008;111:4039-4047. https://doi.org/10.1182/blood-2007-03-081018
- Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma 2006;47:1553-1556. https://doi.org/10.1080/10428190600647723
- Solves P, de la Rubia J, Jarque I, et al. Liver disease as primary manifestation of multiple myeloma in a young man. Leuk Res 1999;23:403-405. https://doi.org/10.1016/S0145-2126(98)00168-4
- Hogan MC, Lee A, Solberg LA, Thome SD. Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol 2002;70:55-59. https://doi.org/10.1002/ajh.10077
- Cheema PK, Zadeh S, Kukreti V, et al. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biol Blood Marrow Transplant 2009;15:686-693. https://doi.org/10.1016/j.bbmt.2009.02.013
- Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995;13 Suppl 2:56-63.
- Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884-892. https://doi.org/10.1182/blood-2012-05-432203
- Chretien ML, Hebraud B, Cances-Lauwers V, et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica 2014;99:1236-1238. https://doi.org/10.3324/haematol.2013.098608
- Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol 2014;89:751-756. https://doi.org/10.1002/ajh.23731
- Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010;89:201-206. https://doi.org/10.1007/s00277-009-0807-6
- Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 2012;158:91-98. https://doi.org/10.1111/j.1365-2141.2012.09124.x
- Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205-3211. https://doi.org/10.1182/blood-2011-06-297853
- Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-355. https://doi.org/10.1038/leu.2011.204
- Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-351. https://doi.org/10.1046/j.1365-2141.1996.5191061.x
- Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883. https://doi.org/10.1056/NEJMoa022340
피인용 문헌
- Bone marrow transplant and pediatric multiple myeloma vol.66, pp.2, 2019, https://doi.org/10.1002/pbc.27528
- Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience vol.138, pp.25, 2017, https://doi.org/10.1182/blood.2021011285